Precision and Promise: Nanotechnology in the Treatment of Head and Neck Cancer and Autoimmune Diseases

Abstract

Nanotechnology has emerged as a transformative approach in the treatment of head and neck cancer (HNC) and autoimmune disorders, offering precise, targeted therapies with minimal systemic toxicity. In HNC, nanocarriers such as liposomes, dendrimers, and carbon nanotubes enable improved drug delivery, while theranostic nanoparticles and nanovaccines enhance immune activation and allow real-time monitoring. These innovations facilitate tumour microenvironment remodelling, overcome drug resistance, and optimize combination immunotherapy. In autoimmune disorders, nanotechnology overcomes the limitations of traditional therapies by enabling specific targeting, reducing long-term side effects, and improving therapeutic outcomes. Nanobiosensors, immunomodulatory nanoparticles, and gene therapy platforms offer advanced diagnostics and personalized treatment, while tolerogenic nanovaccines promote immune tolerance and tissue regeneration. The ability to tailor nanoparticles based on disease-specific markers and immune cell behaviour offers immense potential for personalized medicine. As clinical research advances, nanotechnology is poised to redefine the treatment landscape, improving patient outcomes, reducing toxicity, and enhancing therapeutic precision.